BWC-0977 is under clinical development by Bugworks Research and currently in Phase I for Bacillus anthracis Infections. According to GlobalData, Phase I drugs for Bacillus anthracis Infections have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BWC-0977’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BWC-0977 is under development for the treatment of Gram-negative bacterial infections like Acinetobacter, Acinetobacter baumannii infections, Pseudomonas aeruginosa infections, Enterococcus faecium infections, Staphylococcus aureus infections, Campylobacter Bacillus anthracis infections, Klebsiella pneumoniae, Escherichia coli infections, Yersinia pestis Infections, Francisella tularensis Infections, Burkholderia pseudomallei Infections (Melioidosis), Burkholderia mallei Infections (Glanders) and Bacillus anthracis Infections. The therapeutic candidate is administered through intravenous and oral routes. The therapeutic candidate acts by targeting DNA gyrase and topoisomerase IV. It was under development for Gram-positive bacterial infections.
Bugworks Research overview
Bugworks Research (Bugworks) develops novel class of antibacterial agents and immunotherapies to treat infection and cancer patients with critical care needs. Bugworks is headquartered in Saratoga, California, the US.
For a complete picture of BWC-0977’s drug-specific PTSR and LoA scores, buy the report here.